Improving antibiotic de-escalation in suspected ventilator-associated pneumonia: An observational study with a pharmacist-driven intervention

Journal of Pharmacy Practice

Volumn 28, Issue 5, 2015, Pages 457-461

  Oxman, David A ^a   Adams, Christopher D ^b   Deluke, Gretchen ^b   Philbrook, Lauren ^b   Ireland, Peter ^b   Mitani, Aya ^b   Panizales, Christia ^b   Frendl, Gyorgy ^b   Rogers, Selwyn O ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

antibiotic de escalation; critical care; pneumonia; ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; NAFCILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC DEESCALATION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL PULMONARY INFECTION SCORE; DECISION SUPPORT SYSTEM; ENTEROBACTER; FEMALE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; INTENSIVIST; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PATIENT CARE; PROSPECTIVE STUDY; PROTEUS; PSEUDOMONAS AERUGINOSA; SCORING SYSTEM; SPUTUM CULTURE; TERTIARY CARE CENTER; VENTILATOR ASSOCIATED PNEUMONIA; CROSS INFECTION; MIDDLE AGED; PHARMACIST; PNEUMONIA, VENTILATOR-ASSOCIATED; PROFESSIONAL STANDARD; TREATMENT WITHDRAWAL; TRENDS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CROSS INFECTION; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PHARMACISTS; PNEUMONIA, VENTILATOR-ASSOCIATED; PROFESSIONAL ROLE; PROSPECTIVE STUDIES; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84942094247     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190014527316     Document Type: Article

References (25)

1. Bergmans DC, Bonten MJ, Gaillard CA, et al. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother. 1997; 39 (4): 527-535.
2. Scheld WM,. Developments in the pathogenesis, diagnosis and treatment of nosocomial pneumonia. Surg Gynecol Obstet. 1991; 172 suppl: 42-53.
3. Niederman MS, Craven DE,. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171 (4): 388-416.
4. Zilberberg MD, Shorr AF, Micek ST, et al. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest. 2008; 134 (5): 963-968.
5. Kollef KE, Schramm GE, Wills AR, et al. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest. 2008; 134 (2): 281-287.
6. Klompas M,. Does this patient have ventilator-associated pneumonia? JAMA. 2007; 297 (14): 1583-1593.
7. Meduri G,. Diagnosis and differential diagnosis of ventilator-associated pneumonia. Clin Chest Med. 1995; 16 (1): 61-93.
8. Fagon JY, Chastre J, Hance AJ, et al. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest. 1993; 103 (2): 547-553.
9. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998; 157 (2): 531-539.
10. Kollef M,. Providing appropriate antimicrobial therapy in the intensive care unit: surveillance vs. de-escalation. Crit Care Med. 2006; 34 (3): 903-904.
11. Micek ST, Heuring TJ, Hollands JM, et al. Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy. 2006; 26 (2): 204-213.
12. Depuydt P, Blot S,. Antibiotic Therapy for ventilator-associated pneumonia: de-escalation in the real world. Crit Care Med. 2007; 35 (2): 632-633.
13. Craven DE, Palladino R, McQuillen DP,. Healthcare-associated pneumonia in adults: Management principles to improve outcomes. Infect Dis Clin North Am. 2004; 18 (4): 939-962.
14. Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002; 122 (6): 2115-2121.
15. Pawar M, Mehta Y, Khurana P, et al. Ventilator-associated pneumonia: incidence, risk factors, outcome, and microbiology. J Cardiothorac Vasc Anesth. 2003; 17 (1): 22-28.
16. Simşek S, Yurtseven N, Gerçekogalu H, et al. Ventilator-associated pneumonias in a cardiothoracic surgery centre postoperative intensive care unit. J Hosp Infect. 2001; 47 (4): 321-324.
17. Singh N, Rogers P, Atwood C, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit: a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000; 162 (2 pt 1): 505-511.
18. Micek S, Ward S, Fraser V, et al. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest. 2004; 125 (5): 1791-1799.
19. Ewig S,. Nosocomial pneumonia: de-escalation is what matters. Lancet Infect Dis. 2011; 11 (3): 155-157.
20. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: a randomized trial. Ann Intern Med. 2000; 132 (8): 621-630.
21. Giantsou E, Liratzopoulos N, Efraimidou E, et al. De-escalation therapy rates are significantly higher by bronchoalveolar lavage than by tracheal aspirate. Intensive Care Med. 2007; 33 (9): 1533-1540.
22. Kane S, Weber R, Dasta J,. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003; 29 (5): 691-698.
23. Leape L, Cullen D, Clapp M, et al. Pharmacist participation on physician rounds and adverse events in the intensive care unit. JAMA. 1999; 282 (3): 267-270.
24. Devlin J, Holbrook A, Fuller H,. The effect of ICU sedation guidelines and pharmacist intervention on clinical outcomes and drug cost. Ann Pharmacotherapy. 1997; 31 (6): 689-695.
25. Wong-Berringer A, Nguyen L, Lee M, et al. An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse. Pharmacotherapy. 2009; 29 (6): 736-743.